Market News / Story
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
Stocktwits ·
Stocktwits reports: Editas Medicine (EDIT) was on investors’ radar on Thursday after Australian authorities cleared the biotech firm’s experimental gene-editing treatment for its first human clinical trial, prompting Wells Fargo to upgrade the stock. EDIT shares gained around 4.7% before paring most of the gains. Animal Studies Show 90% Reduction In Bad Cholesterol Level On Thursday, Editas said it received approval to begin the Phase 1/2 Strive trial of EDIT-401 in Australia. The treatment…
Related stories
India’s central bank hikes rates for the first time since 2023 as inflation risks buildRead story summary
The Reserve Bank of India on Wednesday raised interest rates for the first time since 2023, joining several major central banks in tightening monetary policy to arrest accelerating inflation. The central bank increased the benchmark repo rate by 25 basis points to a 1-year high of 5.50%, in line with expectations of economists polled by Reuters. India’s ...
VIEW SOURCE